SCHEMBL30718490

SCHEMBL30718490

Cc1noc(C)c1-c1cccc2nc(N)sc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.53
ASH1L Q9NR48 1/20 0.43
BRD2 P25440 1/20 0.41
CYP1A2 P05177 8/20 0.39
CYP3A4 P08684 8/20 0.39
CLK4 Q9HAZ1 7/20 0.39
HSD17B10 Q99714 7/20 0.39
ALOX15 P16050 5/20 0.39
CYP2C19 P33261 5/20 0.39
ALDH1A1 P00352 5/20 0.39
USP2 O75604 5/20 0.39
CYP2D6 P10635 3/20 0.39
CYP2C9 P11712 2/20 0.39
TSHR P16473 4/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
CASP3 P42574 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17632626 0.83 BRD4 (0.56) BRD4BRD2CYP1A2CYP3A4CLK4
SCHEMBL30248426 0.79 BRD4 (0.54) BRD4BRD2CYP3A4HSD17B10ALDH1A1
SCHEMBL34471204 0.74 ASH1L (0.43) BRD4ASH1LCYP1A2CYP3A4HSD17B10
SCHEMBL28490776 0.74 BRD4 (0.58) BRD4CYP1A2CYP3A4HSD17B10CYP2C19
SCHEMBL2176153 0.72 BRD4 (0.44) BRD4BRD2CYP1A2CYP3A4CLK4
SCHEMBL17632247 0.72 BRD4 (0.64) BRD4CYP1A2CYP3A4HSD17B10CYP2C19
SCHEMBL14266208 0.71 BRD4 (0.42) BRD4BRD2CYP1A2CYP3A4CLK4
SCHEMBL30312094 0.71 ASH1L (0.47) ASH1LALDH1A1MEN1KMT2ANPC1
SCHEMBL29013237 0.71 ASH1L (0.47) ASH1LALDH1A1MEN1KMT2ANPC1
SCHEMBL289210 0.70 SMN1; SMN2 (0.56) ASH1LCYP1A2CYP3A4HSD17B10CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547247-A2 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2025-05-07 EP disclosed
WO-2024006956-A9 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-04-11 WO disclosed
WO-2024006956-A2 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-04 WO disclosed